Skip to main content
SupplementScience

Benefits of Milk Thistle (Silymarin)

This content is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before starting any supplement. Full disclaimer

Evidence-Based Benefits

  • Hepatoprotection via antioxidant activity — silymarin scavenges reactive oxygen species (ROS) and inhibits lipid peroxidation in hepatocytes, reducing oxidative damage. A systematic review by Saller et al. (2001, n=452 across 7 RCTs) found significant reductions in liver-related mortality in cirrhosis patients.
  • Liver enzyme reduction — a meta-analysis by Zhong et al. (2017, n=587) demonstrated silymarin significantly reduced ALT and AST levels in NAFLD patients compared to placebo, with mean reductions of 9.5 U/L and 7.3 U/L respectively.
  • Anti-fibrotic effects — silymarin inhibits hepatic stellate cell activation and reduces collagen deposition. Ferenci et al. (1989, n=170) showed improved survival in alcoholic cirrhosis patients treated with 420mg/day silymarin over 2 years.
  • Protein synthesis stimulation — silybin stimulates ribosomal RNA polymerase I in hepatocytes, accelerating protein synthesis and promoting regeneration of damaged liver tissue (Sonnenbichler & Zetl, 1986).
  • Anti-inflammatory properties — silymarin inhibits NF-κB activation and reduces TNF-α, IL-1β, and IL-6 production in liver tissue, attenuating hepatic inflammation (Polyak et al., 2010).

What the Research Says

Milk thistle is the most extensively researched herbal hepatoprotectant. The landmark Ferenci et al. (1989) RCT demonstrated that 420mg/day silymarin significantly improved survival in patients with alcoholic cirrhosis over a 2-year period. Saller et al. (2001) conducted a systematic review confirming silymarin's hepatoprotective effects across multiple liver conditions. More recently, Zhong et al. (2017) published a meta-analysis specifically evaluating silymarin in NAFLD, finding significant reductions in liver enzymes. The HALT-C trial (2012, n=1049) tested silymarin at higher doses (420mg and 700mg three times daily) in hepatitis C patients, finding dose-dependent reductions in ALT. While silymarin's poor oral bioavailability has been a limitation, phytosome formulations (silymarin-phosphatidylcholine complex) have demonstrated 4-10x improved absorption in pharmacokinetic studies.

Related Conditions

Liver Health
Full Milk Thistle (Silymarin) Guide

References

  1. (). Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. Journal of Hepatology. DOI
  2. (). The use of silymarin in the treatment of liver diseases. Drugs. DOI
  3. (). The therapeutic effect of silymarin in the treatment of nonalcoholic fatty disease: A meta-analysis (PRISMA) of randomized control trials. Medicine. DOI
  4. (). Identification of hepatoprotective flavonolignans from silymarin. Proceedings of the National Academy of Sciences. DOI